Treatment of disseminated malignant melanoma with high‐dose oral BCG

Thirty patients with unresectable disseminated melanoma (Stage IV) were treated with Bacillus Calmette‐Guerin (BCG) (Moreau strain—Rio de Janeiro) by mouth, with weekly doses ranging between 200 mg and 28,000 mg. Five patients died in the first two months of treatment. Of the remaining 25 patients,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 1981-09, Vol.48 (6), p.1353-1362
Hauptverfasser: Varella, Antonio Drauzio, Bandiera, Dino Carlos, De Amorim, Antonio R., Calvis, Luciano A., Santos, Ivan Oliveira, Escaleira, Narcisco, Gentil, Fernando
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1362
container_issue 6
container_start_page 1353
container_title Cancer
container_volume 48
creator Varella, Antonio Drauzio
Bandiera, Dino Carlos
De Amorim, Antonio R.
Calvis, Luciano A.
Santos, Ivan Oliveira
Escaleira, Narcisco
Gentil, Fernando
description Thirty patients with unresectable disseminated melanoma (Stage IV) were treated with Bacillus Calmette‐Guerin (BCG) (Moreau strain—Rio de Janeiro) by mouth, with weekly doses ranging between 200 mg and 28,000 mg. Five patients died in the first two months of treatment. Of the remaining 25 patients, two (8%) showed complete regression, and one (4%) partial regression. Seven patients (28%) had stabilization of the disease for a six‐month period, and 15 (60%) had progression of the disease. Complete and partial regressions were seen only in patients with extravisceral (subcutaneous) metastases, and were associated with a longer survival time. Regression of the subcutaneous metastatic nodules was always accompanied by the following local phenomena: increased temperature; local inflammation; softening, pain and pruritus at the nodule site; and a gradual decrease in size. At the site of the tumor mass, a hypochromic halo appeared. This halo remained permanently and was pathognomonic of the metastatic nodule rejection. When the halo was fully established, the inflammatory infiltrate was minimal and the malignant cells disappeared. If the area contained hairs, they underwent complete albinization. Serial biopsies of the nodules undergoing inflammatory changes and decreased consistency exhibited an intense cellular infiltration of lymphocytes, macrophages, and plasma cells around the malignant cells. This sometimes simulated lymphoid follicle formation involving the melanoma cells associated with necrosis in a centripetal way. Some patients with visceral metastases (particularly pulmonary) had an unexpectedly long survival, apparently associated with interruption of the growth rate of the masses. Eleven out of 20 deaths were due to cerebral metastases. When cerebral disease was diagnosed, BCG was discontinued and the administration of corticoids was usually associated with a disappearance of the inflammatory signs at the nodule sites, but with progression of the disease. Toxicity was minimal.
doi_str_mv 10.1002/1097-0142(19810915)48:6<1353::AID-CNCR2820480617>3.0.CO;2-N
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15450655</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15450655</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5007-8964c9b66667c7a8d8d971e3219595a483df4a76f30590f6b4e3fc539de1e2813</originalsourceid><addsrcrecordid>eNqVkN1q20AQhZfSkLhpH6Ggq9BeyJn91a5bCqnyC8GGkkKhF8NaGsUqkpVqZULu-gh9xjxJ1tgJNBeBzs0wnJlzho-xnMOYA4hDDi5LgSvxgTsbB64_Kjsxn7nUcjI5ujhO82n-TVgByoLh2Rc5hnE--yTS6Ss2erp-zUYAYFOt5I899iaEX3HMhJa7bDcDIY1WI3Z61ZMfWloOSVclZR0CtfXSD1QmrW_q66WPSkuNX3atT27rYZEs6uvF_Z-_ZRco6XrfJF_zs7dsp_JNoHfbvs--n55c5efp5ezsIj-6TAsds1PrjCrc3MTKiszb0pYu4yQFd9ppr6wsK-UzU0nQDiozVySrQktXEidhudxnBxvfm777vaIwYFuHgpr4H3WrgFwrDUbruPhzs1j0XQg9VXjT163v75ADrinjmhOuOeEjZVQWDa4pI0bK-C9llAiYz1DgNLq_376xmrdUPnlvsUa92ui3dUN3_xf9YvIzRT4AUKyZyQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15450655</pqid></control><display><type>article</type><title>Treatment of disseminated malignant melanoma with high‐dose oral BCG</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Varella, Antonio Drauzio ; Bandiera, Dino Carlos ; De Amorim, Antonio R. ; Calvis, Luciano A. ; Santos, Ivan Oliveira ; Escaleira, Narcisco ; Gentil, Fernando</creator><creatorcontrib>Varella, Antonio Drauzio ; Bandiera, Dino Carlos ; De Amorim, Antonio R. ; Calvis, Luciano A. ; Santos, Ivan Oliveira ; Escaleira, Narcisco ; Gentil, Fernando</creatorcontrib><description>Thirty patients with unresectable disseminated melanoma (Stage IV) were treated with Bacillus Calmette‐Guerin (BCG) (Moreau strain—Rio de Janeiro) by mouth, with weekly doses ranging between 200 mg and 28,000 mg. Five patients died in the first two months of treatment. Of the remaining 25 patients, two (8%) showed complete regression, and one (4%) partial regression. Seven patients (28%) had stabilization of the disease for a six‐month period, and 15 (60%) had progression of the disease. Complete and partial regressions were seen only in patients with extravisceral (subcutaneous) metastases, and were associated with a longer survival time. Regression of the subcutaneous metastatic nodules was always accompanied by the following local phenomena: increased temperature; local inflammation; softening, pain and pruritus at the nodule site; and a gradual decrease in size. At the site of the tumor mass, a hypochromic halo appeared. This halo remained permanently and was pathognomonic of the metastatic nodule rejection. When the halo was fully established, the inflammatory infiltrate was minimal and the malignant cells disappeared. If the area contained hairs, they underwent complete albinization. Serial biopsies of the nodules undergoing inflammatory changes and decreased consistency exhibited an intense cellular infiltration of lymphocytes, macrophages, and plasma cells around the malignant cells. This sometimes simulated lymphoid follicle formation involving the melanoma cells associated with necrosis in a centripetal way. Some patients with visceral metastases (particularly pulmonary) had an unexpectedly long survival, apparently associated with interruption of the growth rate of the masses. Eleven out of 20 deaths were due to cerebral metastases. When cerebral disease was diagnosed, BCG was discontinued and the administration of corticoids was usually associated with a disappearance of the inflammatory signs at the nodule sites, but with progression of the disease. Toxicity was minimal.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(19810915)48:6&lt;1353::AID-CNCR2820480617&gt;3.0.CO;2-N</identifier><identifier>PMID: 7023654</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Administration, Oral ; Adult ; Aged ; BCG Vaccine - administration &amp; dosage ; BCG Vaccine - therapeutic use ; Clinical Trials as Topic ; Female ; Humans ; Male ; Melanoma - pathology ; Melanoma - therapy ; Middle Aged ; Neoplasm Metastasis ; Prognosis ; Skin Neoplasms - pathology ; Skin Neoplasms - therapy</subject><ispartof>Cancer, 1981-09, Vol.48 (6), p.1353-1362</ispartof><rights>Copyright © 1981 American Cancer Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c5007-8964c9b66667c7a8d8d971e3219595a483df4a76f30590f6b4e3fc539de1e2813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27928,27929</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7023654$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Varella, Antonio Drauzio</creatorcontrib><creatorcontrib>Bandiera, Dino Carlos</creatorcontrib><creatorcontrib>De Amorim, Antonio R.</creatorcontrib><creatorcontrib>Calvis, Luciano A.</creatorcontrib><creatorcontrib>Santos, Ivan Oliveira</creatorcontrib><creatorcontrib>Escaleira, Narcisco</creatorcontrib><creatorcontrib>Gentil, Fernando</creatorcontrib><title>Treatment of disseminated malignant melanoma with high‐dose oral BCG</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Thirty patients with unresectable disseminated melanoma (Stage IV) were treated with Bacillus Calmette‐Guerin (BCG) (Moreau strain—Rio de Janeiro) by mouth, with weekly doses ranging between 200 mg and 28,000 mg. Five patients died in the first two months of treatment. Of the remaining 25 patients, two (8%) showed complete regression, and one (4%) partial regression. Seven patients (28%) had stabilization of the disease for a six‐month period, and 15 (60%) had progression of the disease. Complete and partial regressions were seen only in patients with extravisceral (subcutaneous) metastases, and were associated with a longer survival time. Regression of the subcutaneous metastatic nodules was always accompanied by the following local phenomena: increased temperature; local inflammation; softening, pain and pruritus at the nodule site; and a gradual decrease in size. At the site of the tumor mass, a hypochromic halo appeared. This halo remained permanently and was pathognomonic of the metastatic nodule rejection. When the halo was fully established, the inflammatory infiltrate was minimal and the malignant cells disappeared. If the area contained hairs, they underwent complete albinization. Serial biopsies of the nodules undergoing inflammatory changes and decreased consistency exhibited an intense cellular infiltration of lymphocytes, macrophages, and plasma cells around the malignant cells. This sometimes simulated lymphoid follicle formation involving the melanoma cells associated with necrosis in a centripetal way. Some patients with visceral metastases (particularly pulmonary) had an unexpectedly long survival, apparently associated with interruption of the growth rate of the masses. Eleven out of 20 deaths were due to cerebral metastases. When cerebral disease was diagnosed, BCG was discontinued and the administration of corticoids was usually associated with a disappearance of the inflammatory signs at the nodule sites, but with progression of the disease. Toxicity was minimal.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>BCG Vaccine - administration &amp; dosage</subject><subject>BCG Vaccine - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Melanoma - pathology</subject><subject>Melanoma - therapy</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Prognosis</subject><subject>Skin Neoplasms - pathology</subject><subject>Skin Neoplasms - therapy</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1981</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkN1q20AQhZfSkLhpH6Ggq9BeyJn91a5bCqnyC8GGkkKhF8NaGsUqkpVqZULu-gh9xjxJ1tgJNBeBzs0wnJlzho-xnMOYA4hDDi5LgSvxgTsbB64_Kjsxn7nUcjI5ujhO82n-TVgByoLh2Rc5hnE--yTS6Ss2erp-zUYAYFOt5I899iaEX3HMhJa7bDcDIY1WI3Z61ZMfWloOSVclZR0CtfXSD1QmrW_q66WPSkuNX3atT27rYZEs6uvF_Z-_ZRco6XrfJF_zs7dsp_JNoHfbvs--n55c5efp5ezsIj-6TAsds1PrjCrc3MTKiszb0pYu4yQFd9ppr6wsK-UzU0nQDiozVySrQktXEidhudxnBxvfm777vaIwYFuHgpr4H3WrgFwrDUbruPhzs1j0XQg9VXjT163v75ADrinjmhOuOeEjZVQWDa4pI0bK-C9llAiYz1DgNLq_376xmrdUPnlvsUa92ui3dUN3_xf9YvIzRT4AUKyZyQ</recordid><startdate>19810915</startdate><enddate>19810915</enddate><creator>Varella, Antonio Drauzio</creator><creator>Bandiera, Dino Carlos</creator><creator>De Amorim, Antonio R.</creator><creator>Calvis, Luciano A.</creator><creator>Santos, Ivan Oliveira</creator><creator>Escaleira, Narcisco</creator><creator>Gentil, Fernando</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>19810915</creationdate><title>Treatment of disseminated malignant melanoma with high‐dose oral BCG</title><author>Varella, Antonio Drauzio ; Bandiera, Dino Carlos ; De Amorim, Antonio R. ; Calvis, Luciano A. ; Santos, Ivan Oliveira ; Escaleira, Narcisco ; Gentil, Fernando</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5007-8964c9b66667c7a8d8d971e3219595a483df4a76f30590f6b4e3fc539de1e2813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1981</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>BCG Vaccine - administration &amp; dosage</topic><topic>BCG Vaccine - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Melanoma - pathology</topic><topic>Melanoma - therapy</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Prognosis</topic><topic>Skin Neoplasms - pathology</topic><topic>Skin Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Varella, Antonio Drauzio</creatorcontrib><creatorcontrib>Bandiera, Dino Carlos</creatorcontrib><creatorcontrib>De Amorim, Antonio R.</creatorcontrib><creatorcontrib>Calvis, Luciano A.</creatorcontrib><creatorcontrib>Santos, Ivan Oliveira</creatorcontrib><creatorcontrib>Escaleira, Narcisco</creatorcontrib><creatorcontrib>Gentil, Fernando</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Varella, Antonio Drauzio</au><au>Bandiera, Dino Carlos</au><au>De Amorim, Antonio R.</au><au>Calvis, Luciano A.</au><au>Santos, Ivan Oliveira</au><au>Escaleira, Narcisco</au><au>Gentil, Fernando</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of disseminated malignant melanoma with high‐dose oral BCG</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1981-09-15</date><risdate>1981</risdate><volume>48</volume><issue>6</issue><spage>1353</spage><epage>1362</epage><pages>1353-1362</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>Thirty patients with unresectable disseminated melanoma (Stage IV) were treated with Bacillus Calmette‐Guerin (BCG) (Moreau strain—Rio de Janeiro) by mouth, with weekly doses ranging between 200 mg and 28,000 mg. Five patients died in the first two months of treatment. Of the remaining 25 patients, two (8%) showed complete regression, and one (4%) partial regression. Seven patients (28%) had stabilization of the disease for a six‐month period, and 15 (60%) had progression of the disease. Complete and partial regressions were seen only in patients with extravisceral (subcutaneous) metastases, and were associated with a longer survival time. Regression of the subcutaneous metastatic nodules was always accompanied by the following local phenomena: increased temperature; local inflammation; softening, pain and pruritus at the nodule site; and a gradual decrease in size. At the site of the tumor mass, a hypochromic halo appeared. This halo remained permanently and was pathognomonic of the metastatic nodule rejection. When the halo was fully established, the inflammatory infiltrate was minimal and the malignant cells disappeared. If the area contained hairs, they underwent complete albinization. Serial biopsies of the nodules undergoing inflammatory changes and decreased consistency exhibited an intense cellular infiltration of lymphocytes, macrophages, and plasma cells around the malignant cells. This sometimes simulated lymphoid follicle formation involving the melanoma cells associated with necrosis in a centripetal way. Some patients with visceral metastases (particularly pulmonary) had an unexpectedly long survival, apparently associated with interruption of the growth rate of the masses. Eleven out of 20 deaths were due to cerebral metastases. When cerebral disease was diagnosed, BCG was discontinued and the administration of corticoids was usually associated with a disappearance of the inflammatory signs at the nodule sites, but with progression of the disease. Toxicity was minimal.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>7023654</pmid><doi>10.1002/1097-0142(19810915)48:6&lt;1353::AID-CNCR2820480617&gt;3.0.CO;2-N</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 1981-09, Vol.48 (6), p.1353-1362
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_15450655
source MEDLINE; Alma/SFX Local Collection
subjects Administration, Oral
Adult
Aged
BCG Vaccine - administration & dosage
BCG Vaccine - therapeutic use
Clinical Trials as Topic
Female
Humans
Male
Melanoma - pathology
Melanoma - therapy
Middle Aged
Neoplasm Metastasis
Prognosis
Skin Neoplasms - pathology
Skin Neoplasms - therapy
title Treatment of disseminated malignant melanoma with high‐dose oral BCG
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T07%3A55%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20disseminated%20malignant%20melanoma%20with%20high%E2%80%90dose%20oral%20BCG&rft.jtitle=Cancer&rft.au=Varella,%20Antonio%20Drauzio&rft.date=1981-09-15&rft.volume=48&rft.issue=6&rft.spage=1353&rft.epage=1362&rft.pages=1353-1362&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/1097-0142(19810915)48:6%3C1353::AID-CNCR2820480617%3E3.0.CO;2-N&rft_dat=%3Cproquest_cross%3E15450655%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15450655&rft_id=info:pmid/7023654&rfr_iscdi=true